Browsing by Author "Ješić, Maja D. (24073164000)"
Now showing 1 - 3 of 3
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication First patient in Serbia with biochemically and genetically diagnosed pyridoxine-dependent epilepsy; [Prvi bolesnik u Srbiji sa biohemijski i genetički dijagnostikovanom piridoksin zavisnom epilepsijom](2017) ;Ješić, Miloš M. (57211511149) ;Ješić, Maja D. (24073164000) ;Buljugić, Svetlana (55339460500)Živanović, Aleksandra (57194553008)Introduction. Pyridoxine-dependent epilepsy (PDE) is a rare autosomal recessive inborn error of metabolism present with early-onset seizures resistant to common anticonvulsants. PDE has been shown to be caused by a defect of a α-aminoadipic semialdehyde dehydrogenase (also known as ALDH7A1 or antiquitin) in the cerebral lysine degradation pathway. Its deficiency results in accumulation of α-aminoadipic semialdehyde (α-AASA), piperideine -6-carboxylate and pipecolic acid, which serve as diagnostic markers in urine, plasma and cerebrospinal fluid of the disease. α-Aminoadipic semialdehyde dehydrogenase is encoded by the ALDH7A1 or antiquitin gene and definite confirmation of diagnosis of PDE is made by genetic analysis. Case report. We present a first patient in Serbia who was diagnosed clinically, biochemically and genetically. We suspected PDE due to drug-resistant seizures in the seventh day of life when we attempted with pyridoxine. Since that time the patient has taken pyridoxine and the seizures have not recured. Our patient had markedly elevated α- AASA in urine while on treatment with individual dosages of pyridoxine. Molecular-genetical analysis identified mutations of the ALDH7A1 (antiquitin) gene. Conclusion. α-AASA is reliable marker to select PDF patient for molecular analysis of the ALDH7A1(antiquitin) gene. Diagnosis is confirmed by molecular- genetical analysis and pyridoxine withdrawal is no longer needed to establish the diagnosis of „definite“ PDE. © 2017, Institut za Vojnomedicinske Naucne Informacije/Documentaciju. All rights reserved. - Some of the metrics are blocked by yourconsent settings
Publication Ketoacidosis at presentation of type 1 diabetes mellitus in children: A retrospective 20-year experience from a tertiary care hospital in Serbia(2013) ;Ješić, Maja D. (24073164000) ;Ješić, Miloš M. (57211511149) ;Stanisavljević, Dejana (23566969700) ;Zdravković, Vera (6603371560) ;Bojić, Vladislav (8302460300) ;Vranješ, Mira (55966816100) ;Trifunović, Danijela (9241771000) ;Necić, Svetislav (6603541845)Sajić, Silvija (24073590000)Diabetic ketoacidosis (DKA) has significant morbidity and mortality and is common at diagnosis in children. The aim of this study was to determine the frequency and clinical characteristics of DKA over a 20-year period among children diagnosed with type 1 diabetes mellitus (T1DM) at University children's hospital in Belgrade, Serbia. The study population comprised of 720 patients (366 boys) diagnosed with type 1 diabetes aged <18 years between January 1992 and December 2011. Of all patients diagnosed with T1DM, 237 (32.9 %) presented with DKA. The majority had either mild (69.6 %) or moderate (22.8 %) DKA. Sixty (55.0 %) of all children under 5 years had DKA compared to sixty-two (20.9 %) in the 5- to 10-year-old group and one hundred fifteen (36.6 %) in the 11- to 18-year-old patients (p < 0.01), while 2.5 % of the entire DKA cohort were in real coma. During the later 10-year period, children less often had DKA at diagnosis compared with the earlier 10-year period (28.0 vs. 37.4 %) (p < 0.01), but the frequency of severe DKA was higher in the age group <5 year and in the age group >11 year during 2002-2011, compared with the earlier 10-year period (12.9 vs. 3.4 %, p < 0.01 and 17.1 vs. 3.8 %, p < 0.01). Conclusion: The overall frequency of DKA in children with newly diagnosed type 1 diabetes decreased over a 20-year period at our hospital. However, children aged <5 years and adolescents are still at high risk for DKA at diagnosis. © 2013 Springer-Verlag Berlin Heidelberg. - Some of the metrics are blocked by yourconsent settings
Publication The first case of benign familial neonatal epilepsy diagnosed in Serbia; [Prvi slučaj benigne familijarne neonatalne epilepsije dijagnostikovan u Srbiji](2021) ;Nikolić, Katarina (57322683900) ;Ješić, Maja D. (24073164000) ;Kojić, Marko (57322563800)Ješić, Miloš M. (57211511149)Introduction. The exact prevalence of benign familial neonatal epilepsy (BFNE) is unknown due to the likelihood of overlooking the disease and not diagnosing the affected patients correctly. The rare autosomal dominant inherited disorder usually occurs within a few days after birth of an otherwise healthy newborn, and disappears after one to four months. Most patients develop no psychomotor deficiencies, nor any other forms of seizures. The disorder is most commonly linked to the KCNQ2 gene, with mutations located on the chromosome 20q13.33 which cause voltage-gated potassium channel changes. This clinically rare condition manifests itself in repeated tonic-clonic episodes of focal and generalized convulsions which are effectively treated with antiepileptic therapy. Case report. We presented a five-day old affected male infant, with genetically proven KCNQ2 gene mutation, in addition to a positive familial history of epilepsy. Seizures did not reoccur after several episodes in the fifth day of life and further psychomotor development of the child proved normal. Conclusion. Neonatal seizures have extensive differential diagnosis. However, BFNE should be suspected when the most common neonatal seizure causes have been excluded, and factors, such as the hereditary factor, in addition to the typical clinical course resembling BFNE, can be observed. Genetic identification of BFNE has resulted in easier and more specific diagnosis of this rare disorder and is therefore the gold standard in its diagnostics. © 2021 Inst. Sci. inf., Univ. Defence in Belgrade. All rights reserved.
